Cyclacel Pharmaceuticals, Inc. (CYCCP)
Chart Events
Performance Outlook
| Previous Close | 7.15 |
| Open | 6.48 |
| Bid | 6.00 x 1100 |
| Ask | 7.25 x 1800 |
| Day's Range | 7.15 - 7.15 |
| 52 Week Range | 5.17 - 11.17 |
| Volume | |
| Avg. Volume | 88 |
| Market Cap | 12.322M |
| Beta (5Y Monthly) | 1.21 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.66 |
| Earnings Date | May 12, 2020 |
| Forward Dividend & Yield | 0.60 (9.26%) |
| Ex-Dividend Date | Oct 14, 2021 |
| 1y Target Est | N/A |
- GlobeNewswire
Cyclacel Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
- Oral Fadraciclib Demonstrating Strong Safety Profile with Continuous Dosing; anticipate entering Phase 2 POC in 2H 2022 - - First Patients Dosed in Phase 1/2 Study of Oral PLK1 Inhibitor CYC140 for Treatment of Advanced Solid Tumors and Lymphomas - - Publication Confirming Fadraciclib Suppresses MCL1 and Synergistic Activity with Venetoclax in CLL - - Cash Runway through Mid-2023 - - Conference Call Scheduled for May 11, 2022 at 4:30 pm EDT - BERKELEY HEIGHTS, N.J., May 11, 2022 (GLOBE NEWSWIR
- GlobeNewswire
Cyclacel Pharmaceuticals to Release First Quarter 2022 Financial Results
BERKELEY HEIGHTS, N.J., May 04, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce first quarter 2022 financial results on Wednesday, May 11, 2022. The company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time on the same day. Conference call information: US/Canada call: (866) 342-8591 / internationa
- GlobeNewswire
Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Cyc140 in Patients With Advanced Solid Tumors and Lymphomas
- CYC140, a Potent and Selective PLK1 Inhibitor to Be Evaluated as a Single Agent Across Multiple Solid Tumor and Lymphoma Types in Streamlined, Registration-Directed Study -BERKELEY HEIGHTS, N.J., April 19, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced dosing of the first patient in the Company’s streamlined, multi-cohort Phase
